Companion Animal Pharmaceuticals Market

Companion Animal Pharmaceuticals Market - Global Forecast to 2022

Report Code: UC 1799 Apr, 2021, by

The companion animal pharmaceuticals market is expected to register significant growth between 2017 and 2022. The key factors responsible for the growth of this market are increasing population of companion animals, rising pet ownership, growing animal healthcare expenditure, rising awareness about zoonotic diseases, and growing concern about pet health and wellbeing. Growing consolidation of the animal health industry is a major trend in the global companion animal pharmaceuticals market.

In this report, the global companion animal pharmaceuticals market is segmented by indication, animal type, distribution channel, and region. Based on indication, this market is further segmented into infectious diseases, dermatological diseases, orthopedic diseases, behavioral diseases, pain, dental diseases, and others. In 2016, the pharmaceuticals used to treat infectious diseases held the largest share of the market. This large share is mainly attributed to increasing adoption of anti-infective drugs such as antibiotics, antimicrobials, and parasiticides (especially endectocides) to treat infectious diseases in companion animals. On the basis of animal type, the market is categorized into dogs, cats, horses, and other companion animals. Pharmaceuticals used for treating dogs accounted for the largest share of the market in 2016. Based on the distribution channel, the market is categorized into veterinary hospitals, veterinary clinics, and retail pharmacies.

North America is the largest regional segment of the market. The markets in Asia-Pacific and Latin America are expected to register the highest growth during the forecast period, primarily due to rising pet ownership, growing disposable income, and increasing awareness about animal health.

Some of the major players competing in this market are Zoetis, Inc. (U.S.), Bayer AG (Germany), Boehringer Ingelheim GmbH (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Vetoquinol (France), Virbac (France), Dechra Pharmaceuticals plc (U.K.), Ceva Sante Animale (France), and Aratana Therapeutics, Inc. (U.S.).

Scope of the Report:

The research report categorizes the global companion animal pharmaceuticals market into the following segments and subsegments:

Global Companion Animal Pharmaceuticals Market, by Indication

  • Infectious Diseases
    • Antibiotics and Antimicrobials
    • Parasiticides
    • Others
  • Dermatological Diseases (Skin Diseases)
  • Orthopedic Diseases
  • Behavioral Disorders
  • Pain
  • Dental Diseases
  • Others

Global Companion Animal Pharmaceuticals Market, by Animal Type

  • Dogs
  • Cats
  • Horses
  • Other Companion Animals

Global Companion Animal Pharmaceuticals Market, by Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Retail Pharmacies

Global Companion Animal Pharmaceuticals Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of Asia-Pacific (RoAPAC)
  • Latin America
  • Middle East and Africa

Table of Contents

1 Introduction
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology
    2.1 Research Approach
    2.2 Market Size Estimation
    2.3 Market Breakdown and Data Triangulation
    2.4 Market Share Estimation
    2.5 Assumptions for the Study

3 Executive Summary

4 Premium Insights

5 Market Overview
    5.1 Introduction 
    5.2 Market Dynamics 
           5.2.1 Drivers
           5.2.2 Restraints
           5.2.3 Opportunities
           5.2.4 Challenges

6 Global Companion Animal Pharmaceuticals Market, By Indication
    6.1 Introduction
    6.2 Infectious Diseases
           6.2.1 Antibiotics and Antimicrobials
           6.2.2 Parasiticides
           6.2.3 Others
    6.3 Dermatologic Diseases (Skin Diseases)
    6.4 Orthopedic Diseases
    6.5 Behavioral Disorders
    6.6 Pain
    6.7 Dental Diseases
    6.8 Others

7 Global Companion Animal Pharmaceuticals Market, By Animal Type
    7.1 Introduction
    7.2 Dogs
    7.3 Cats
    7.4 Horses
    7.5 Other Companion Animals

8 Global Companion Animal Pharmaceuticals Market, By Distribution Channel
    8.1 Introduction
    8.2 Veterinary Hospitals
    8.3 Veterinary Clinics
    8.4 Retail Pharmacies

9 Global Companion Animal Pharmaceuticals Market, By Region
    9.1 Introduction
    9.2 North America
           9.2.1 U.S.
           9.2.2 Canada
    9.3 Europe
           9.3.1 Germany
           9.3.2 U.K.
           9.3.3 France
           9.3.4 Italy
           9.3.5 Spain
           9.3.6 Rest of Europe (RoE)
    9.4 Asia Pacific (APAC)
           9.4.1 China
           9.4.2 Japan
           9.4.3 India
           9.4.4 Rest of Asia Pacific (RoAPAC)
    9.5 Latin America
    9.6 Middle East and Africa

10 Competitive Landscape
     10.1 Introduction
     10.2 Vendor Dive Overview
             10.2.1 Vanguards
             10.2.2 Innovators
             10.2.3 Emerging
             10.2.4 Dynamic
     10.3 Competitve Benchmarking 
             10.3.1 Product Portfolio Assesment
             10.3.2 Business Strategies Analysis

11 Company Profiles*

(Business Overview, Key Financials, Company Scorecard, Recent Developments)
     11.1 Zoetis, Inc. 
     11.2 Bayer AG
     11.3 Boehringer Ingelheim GmbH
     11.4 Eli Lilly and Company
     11.5 Merck & Co., Inc.
     11.6 Vetoquinol
     11.7 Virbac
     11.8 Dechra Pharmaceuticals PLC
     11.9 Ceva Sante Animale
     11.10 Aratana Therapeutics, Inc.

12 Appendix
     12.1 Insights of Industry Experts 
     12.2 Discussion Guide 
     12.3 Available Customizations 
     12.4 Introducing RT: Real Time Market Intelligence 
     12.5 Related Reports

*The List of Companies Mentioned Above is Indicative Only and Might Change During the Course of the Study.
*Details on Key Financials Might Not Be Captured in Case of Unlisted Companies.

Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
8 1 5 4 5  
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)

Get in-depth analysis of the COVID-19 impact on the Companion Animal Pharmaceuticals Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Companion Animal Pharmaceuticals Market

Request For Special Pricing
Report Code
UC 1799
Available for Pre-Book
Choose License Type
Prebook Now
Request Customization
Speak to Analyst
Speak to Analyst
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
  • What are the Known and Unknown Adjacencies Impacting the Companion Animal Pharmaceuticals Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
©2021 MarketsandMarkets Research Private Ltd. All rights reserved

Digital Virtual Assistant - MarketsandMarkets